Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer
Authors:
- Elizabeth A. PoplinEPElizabeth A. Poplin
- Jacqueline K. BenedettiJBJacqueline K. Benedetti
- Norman C. EstesNENorman C. Estes
- Daniel G. HallerDHDaniel G. Haller
- Robert J. MayerRMRobert J. Mayer
- Richard M. GoldbergRGRichard M. Goldberg
- Geoffrey R. WeissGWGeoffrey R. Weiss
- Saul E. RivkinSRSaul E. Rivkin
- John S. MacdonaldJMJohn S. Macdonald
- 20 March 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (9) , 1819-1825
Abstract
Purpose: Modest toxicity and possibly enhanced activity makes continuous-infusion fluorouracil (FU) an attractive alternative to FU plus leucovorin (FU/LV) for the adjuvant treatment of colorectal cancer. Intergroup trial 0153 (Southwest Oncology Group trial 9415) was developed to compare the efficacy of continuous-infusion FU (CIFU) plus levamisole to FU/LV plus levamisole in the adjuvant treatment of high-risk Dukes' B2 and C1 or C2 colon cancer. Patients and Methods: After surgery, patients were randomly assigned to CIFU 250 mg/m2/d for 56 days every 9 weeks for three cycles or FU 425 mg/m2 and LV 20 mg/m2 daily for 5 days every 28 to 35 days for six cycles. All patients received levamisole 50 mg tid for 3 days every other week. The primary end point was overall survival (OS). Results: The study closed in December 1999 after an interim analysis demonstrated little likelihood of CIFU showing superiority to FU/LV within the stipulated hazard ratio. A total of 1,135 patients were registered. At least one grade 4 toxicity occurred in 39% of patients receiving FU/LV and 5% of patients receiving CIFU. However, almost twice as many patients receiving CIFU discontinued therapy early compared with those receiving FU/LV. The 5-year OS is 70% (95% CI, 66% to 74%) for FU/LV and 69% (95% CI, 64% to 73%) for CIFU. The corresponding 5-year disease-free survival (DFS) is 61% (95% CI, 56% to 65%) and 63% (95% CI, 59% to 68%), respectively. For all patients, 5-year OS is 83%, 74%, and 55%; 5-year DFS is 78%, 67%, and 47% for N0, N1, and N2-3, respectively. Conclusion: CIFU had less severe toxicity but did not improve DFS or OS in comparison with bolus FU/LV.Keywords
This publication has 31 references indexed in Scilit:
- Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parametersOncogene, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized TrialJournal of Clinical Oncology, 2003
- A New TNM Staging Strategy for Node-Positive (Stage III) Colon CancerAnnals of Surgery, 2002
- Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trialThe Lancet, 2000
- Phase III Study of Bolus Versus Infusion Fluorouracil With or Without Cisplatin in Advanced Colorectal CancerJNCI: Journal of the National Cancer Institute, 1996
- Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: A southwest oncology group pilot studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011JNCI: Journal of the National Cancer Institute, 1988